#China #Shanghai #AI Technology #Fosun Pharmaceutical #PharmAID

Fosun Pharmaceutical's Embrace of AI Technology

Fosun Pharmaceutical, a trailblazer in the pharmaceutical and healthcare sector, is at the forefront of integrating artificial intelligence (AI) into its operational framework. As AI technology continues to reshape industries globally, Fosun Pharma recognizes its transformative potential, focusing on enhancing drug development, precision medicine, and medical imaging.

Incorporating AI across various dimensions of its business, Fosun Pharma has developed the PharmAID Decision Intelligence Platform, designed to streamline processes and enhance decision-making in drug research and development (R&D). This innovative platform employs advanced AI models to create a comprehensive intelligent decision-making network that influences every stage of drug development. With features that encompass everything from toxicity analysis to medical writing, PharmAID is revolutionizing how drugs are developed and commercialized.

The PharmAID Decision Intelligence Platform

Fosun Pharma's PharmAID platform is notable for being the first of its kind in the pharmaceutical industry, combining leading AI technologies with practical applications in R&D. By integrating with Deepseek R1, a global leader in AI modeling, the platform has significantly advanced the accuracy of decision-making processes, increasing content generation accuracy by 50%. This leads to faster, more reliable outcomes in drug development.

The platform also provides features such as AI medical writing and enhancement of information retrieval speeds and accuracy—offering considerable efficiency boosts to R&D teams. Additionally, it supports smart training initiatives for sales teams, promoting more effective marketing strategies and improving corporate management efficiencies.

AI-Driven Collaborations and Innovations

Fosun Pharm’s commitment to AI-driven innovation is exemplified by its partnerships with notable AI firms such as Insilico Medicine. Such collaborations aim to synergize cutting-edge AI capabilities with deep pharmaceutical expertise to foster breakthroughs in drug development.
In early 2025, a strategic alliance was formed with DP Technology for AI-assisted drug research, signaling Fosun's proactive approach to melding AI with traditional drug modeling techniques. This partnership seeks to harness sophisticated AI algorithms to better understand drug targets, thus accelerating the discovery process.

Building an AI+X Ecosystem in Healthcare

Beyond pharmaceuticals, Fosun Aitrox, a subsidiary of Fosun Pharma, is pioneering an `AI+X` model that enhances healthcare services through AI applications. Offering comprehensive medical AI solutions across multiple disciplines—including radiology, pathology, and cardiology—this approach aims to improve early diagnosis and streamline treatment processes in hospitals and clinics. The operational reach of Fosun Aitrox spans over 20 provinces in China, aiming to support healthcare providers in their quest for excellence and accessibility.

The use of AI in diagnostics has proven critical, with initiatives focusing on improving the analysis of medical imaging data. Fosun Aitrox's AI-powered diagnostics tools assist medical professionals in identifying conditions with heightened precision and efficiency, thereby enhancing patient care—particularly in underserved areas.

Future Prospects for Fosun Pharma's AI Integration

Fosun Pharmaceutical is steadfast in its commitment to innovation, aiming to deepen AI investments across its entire business model. The company’s efforts to integrate AI at various levels not only place it in a competitive position within the pharmaceutical landscape but also pave the way for significant advancements in global healthcare quality. As it continues to foster partnerships and invests in groundbreaking technologies, Fosun Pharma is poised to lead the charge into an AI-enhanced future for healthcare and pharmaceuticals.

About Fosun Pharma

Founded in 1994, Fosun Pharmaceutical (Group) Co., Ltd., listed under stock codes 600196.SH and 02196.HK, is a leading global pharmaceutical and healthcare conglomerate. With a focus on addressing clinical needs through innovative products and strategic collaborations, Fosun Pharma is committed to solving healthcare challenges and advancing global health standards. For more information, visit www.fosunpharma.com.